Mmit formulary data “Ryan [Witherington] and the team at MMIT have been great partners in our initiatives to analyze and communicate payer policy data for our product through innovative field tools, both MMIT-developed and developed by us using MMIT data. January 11, 2025 - The formulary report in VAMP has been refreshed with the MMIT formulary data file dated 01/03/2025. Yet despite these concerns, Wegovy is currently covered at 54% across all channels, according to MMIT’s Analytics policy and restriction data. Analyze pharmacy and medical benefit landscapes using payer and PBM data analytics. Access Fingertip now! About Us. Clinical Lab Data: Data from tests performed in clinical settings to diagnose or monitor patients’ health conditions. In a first-of-its-kind offering, MMIT integrates all of these RWD sources with payer coverage and clinical pathways data, creating a unified record of the patient journey. Once standardized, the information is accumulated and published in books or web sites such as this. MMIT Reach helps to segment and engage with the market by breaking down key decision-makers. Lab data is often the key driver in diagnostic and therapeutic decisions. Download the free app today. Andrew Rouff is a senior consultant on the Advisory Services team at MMIT. For example, a patient might not be given an ICD-10 code or a diagnosis on every visit, but there might be a pathology report or notes history that Deidentified lab data offers immense value to pharma companies. Since lab tests often represent one of the earliest data points in a patient’s diagnostic journey, pharma companies are using lab results to identify potential patients and their physicians in time to directly impact the patient’s treatment plan. ” On Nov. MMIT’s Analytics solution delivers the most comprehensive formulary, medical policy and restriction information to evaluate patient access for your brand and competitors. Our in-depth writing covers the companies, people, catalysts and trends that create the richly textured contours of the health care and drug industry. 4M over 2 rounds from 3 investors. In this use case, learn how the company used MMIT’s API to get access to formulary, medical policy, and restriction data, helping the client integrate this information into their existing software As a solution consultant for MMIT, Carolyn Zele helps pharmaceutical manufacturers simplify market access and prepare for launch success. Explore DRG's Fingertip Formulary. Understand how a patient gets on or off therapy; Help patients overcome barriers to treatment; Use lab data to target the right physicians and Patient Populations About Us. Managed Markets Insight & Technology While the formulary inclusion rule doesn’t completely negate the establishment of a negotiated price, it should help offset the revenue loss. MMIT Network has 77 competitors. “2023 National Preferred Formulary Exclusions,” Express Scripts. Download this brochure to see how MMIT’s Coverage Search application enables field teams to deliver brand-specific messaging to HCPs and address any access questions that they have. • Meet internal brand standards through highly configurable templates. MMIT is now offering the only configurable, web-based market access software that tracks weekly patient access data performance across geographies, payer channels and specific accounts during critical launch milestones. . MMIT’s Zitter Insights panel consists of more than 500 experts from both payers and IDNs. Real-world data (RWD) gives pharma a 360-degree view of all the different touchpoints of the healthcare system and how those customers interact. Apr 27, 2023 · As a solution consultant for MMIT, Carolyn Zele helps pharmaceutical manufacturers simplify market access and prepare for launch success. MMIT’s real-world data solution provides critical insights for manufacturers across the clinical and commercial life cycle. A scientist by training, Andrew uses market research and analytics to help clients understand the unique opportunities and challenges in providing access for their brands. Kala Bala, SVP, Enterprise Access and Data Expertise: One of the top challenges being flagged by our clients is the impact of the Inflation Reduction Act’s various provisions, especially on formulary changes, including the addition of newly launched brands to Medicare formularies. Proactive companies are using this robust data to accelerate time to treatment, whether in the clinical setting or for existing therapies. Today, MMIT’s solutions are powered by NorstellaLinQ—the industry’s most complete and connected data asset—which consists of MMIT’s proprietary payer, formulary and provider data alongside critical real-world patient data such as open and closed claims, lab data, and EMR/EHR data. The panel’s most recent Panelist Satisfaction Survey, conducted in 2023, offers insights into this influential population. • Adhere to state and federal publishing guidelines. Sep 11, 2024 · Leslie Small . Our Zitter Insights panel represents top health plans, PBMs and IDNs to provide meaningful insights to our clients. Tracking disease progression over time Integrating lab data into the market access data mix introduces another dimension of the patient journey. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. Obtaining a current, validated source of truth for payer contact information and PBM contact information will help your team reach top targets. “Skyrocketing Growth in PBM Formulary Exclusions Continues to Raise Concerns About Patient Access,” AmerisourceBergen Xcenda. She analyzes pharmaceutical and medical claims datasets, conducts patient journey analyses, and visualizes data to help clients optimize utilization. As the leading provider of market access data, analytics and insights, our expert teams of pharmacists, clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. Monthly we monitor status and restriction changes for over 98% of covered lives. MMIT’s real-world data assets are powered by NorstellaLinQ, the first and only fully integrated data asset combining real-world data and Norstella’s proprietary intelligence from the most trusted brands in the industry – Citeline, Evaluate, MMIT, Panalgo and The Dedham Group. MMIT is now offering the only configurable, web-based market access software—integrated with our Analytics solution—that tracks weekly patient access data performance across geographies, payer channels and specific accounts during critical launch milestones. We’ll see more and more linkage of open and closed claims data with lab data, EMR data, and other real-world datasets featuring both structured and unstructured data. Q: What role does the Implementation team fill at MMIT? A: The Implementation team manages all the task-related work to con- Healthcare data encompasses a wide range of information related to health and healthcare delivery. Want to learn more? Connect with our team today to gain access to MMIT Analytics. Predict payer and PBM responses to new drug launches through market access analytics. His team provides market access context and a market research narrative for the company's data and technology products. Welcome back to MMIT’s Market Access 101 series, in which we unpack the complexities of market access via a series of blog posts. Given historical data, IDNs and payers are likely to review biosimilars and make formulary changes on different timelines, which can impact manufacturers’ contracting strategies. Payers must expend a significant effort to process and mail notification letters to inform their members about any formulary changes. As the leading provider of market access data, analytics and insights, our expert teams of pharmacists, clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. Founded by Amir Goldman in the year 1994. Trak, an MMIT application that pharmaceutical sales teams use to create FormTrak cards to communicate formulary coverage in a specific area, and Formulary Search, MMIT’s app that allows users to look up drug coverage. MMIT offers an end-to-end solution that enables payers to manage both pharmacy and medical benefit drugs in one platform. MMIT Strategic Launch Report provides drug manufacturers with a realistic view of payers’ coverage adoption rates and utilization management within the first year post-launch. simplifies HCP prescribing can be even harder. There are many ways to consume this Formulary data, and we hope to highlight some basic scenarios in the examples below. In a recent survey of 125 pharma executives, nearly half cited data integration and cleanliness as the primary roadblocks to adopting technologies like AI. To learn how MMIT can help your team improve product positioning and coverage, see our Market Access solutions. Director of Commercial Solutions, MMIT: RWD can even encompass data that we don’t normally think about, like specific physician notes and other kinds of unstructured data. MMIT’s suite of data products helps pharma companies get their drugs to market, ensure patients can access them, and accurately forecast payer and patient uptake. Whether you’re combining MMIT’s data with other third-party data sources or delivering up-to-date information to HCPs and patients, our cutting-edge technology and world Lance Wolkenbrod, Sr. Boost Market Access with Lab and Claims Data Use real-world data to predict where your potential patients will be located, identify prescribing physicians and specialists, and engage the right physicians with the best messaging at the About Us. Field teams can create promotional cards with industry-leading patient access data within Veeva CRM, the most dominant pharma field team CRM. As a solution consultant for MMIT, Carolyn Zele helps pharmaceutical manufacturers simplify market access and prepare for launch success. Jan 16, 2025 · The past few years saw the launch of several direct-to-consumer (DTC) programs, including Amazon One Medical and Mark Cuban’s Cost Plus Drugs. Formulary data are provided by MMIT, LLC, as of May 2024. We Illuminate the entire patient journey offering comprehensive data and insights from diagnosis to treatment, while helping you remove barriers to access, ensuring your treatments reach those who need them most. A leading healthcare IT company was seeking to enhance its software offering by embedding comprehensive drug coverage and patient access data. “Need to know if that drug is covered? Are you a prescribing doc and want to select a preferred drug for your patient?” MMIT’s drug status information is updated nightly, ensuring you have the data points needed to… A leading healthcare IT company was seeking to enhance its software offering by embedding comprehensive drug coverage and patient access data. MMIT Formulary Insights provides unparalleled visibility into health system formularies, decision-making, and contracting insights to develop a data-driven IDN approach. For example, for a managed Medicaid plan with a state-mandated formulary, the state itself is the controller. Dinesh Kabaleeswaran is the senior vice president of Advisory Services at MMIT. Raised a total funding of $27. Formulary Management • Create submission-ready regulatory files automatically. Your single source of reliable and current drug coverage and restriction information. Source:MACPAC/IMPAQ analysis of December 2017 MMIT formulary data. For nearly two decades MMIT has been solely focused on solving the “what and why” of drug coverage and has been a About Us. Director of Commercial Solutions, MMIT: Pharma companies basically have three kinds of customers—patients, physicians, and payers/PBMs. Why Updated Health Plan Enrollment Data Is Crucial in the Wake of Medicaid Changes October 26, 2023 About Us. We help you improve payer coverage, influence product Oct 17, 2024 · As the leading provider of market access data, analytics and insights, our expert teams of pharmacists, clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. SCHEDULE A MEETING MMIT Analytics Solution Overview Overview MMIT’s industry-leading platform, Analytics, empowers teams According to MMIT data, FDA approval and interchangeability claims are seen by payers as most important when considering whether to add an adalimumab biosimilar to their formulary. January 17, 2025 - The MMIT contacts have been refreshed. IQVIA LAAD 2022, Medicare patients. In theory, this means that any drug that is not listed on a payer or PBM’s formulary can still be prescribed—if, of course, providers are willing to take on the administrative burden of requesting an exception. AIS Health maintains journalistic independence from our parent company, MMIT. With our real-world data, expertise and insights, we work together to illuminate your path to patients. The report is paired with consensus forecast data from our partner, Evaluate, for currently approved and pipeline agents within the target indication, to help you identify competitors and challenges and proactively plan Sep 28, 2021 · “With Panalgo’s best-in-class platform, MMIT’s expansive base of over 1,300 biopharma and payer customers, and its gold-standard formulary data, we are well-equipped to support clients from end to end. Data from MMIT Formulary bridge through January 2023 Nomenclature, and Xponent PlanTrak using week ending 1/20/2023; only considers bridged volume; excludes cash and mail order data. That’s where we come in. Nov 21, 2024 · MMIT is a data provider providing information to answer key business questions related to prescription drug access. Feb 16, 2023 · SOURCES: “Formulary Drug Removals,” CVS Health. RJ Health, an MMIT company, delivers industry standard specialty drug pricing, coding and reimbursement solutions to support payer and provider alignment. Gia Yaccarino is a Senior Clinical Advisor on MMIT’s data operations team. To maximize market share, manufacturers should aim to launch their product as soon as possible and drive brand awareness with patients and prescribers. Harmonized data is a prerequisite for generating actionable insights, with or without sophisticated data science engines. Drug formulary status and medical policies at your fingertips. In 2024, several manufacturer-designed DTC programs, such as LillyDirect and PfizerForAll, have been added to the mix, demonstrating pharma’s continuing shift toward an integrated model of patient care. The controller may be a payer, a pharmacy benefits manager (PBM), a managed care organization (MCO), or a government entity. Recent MMIT data reveals that approximately 75% of all formularies are still considered open. Transaction data are provided by SHS database as of May 2024. Acquired by Susquehanna Growth Equity. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced. MMIT data provides the formulary status of prescription drugs. Every month, our team evaluates a variety of pricing and coding updates. Who is Zitter Insights/MMIT? Acquired in early 2019, Zitter Insights is a division of MMIT that brings market research and helps address the “why” of market access. MMIT Navigator is the leading formulary management and publishing solution, enabling pharmacy teams to simplify drug benefit management and communicate that coverage clearly to providers and patients. Please review and make changes to your contacts by February 8th. 1, 2021, Jordan Menzin, CTO, will become CEO of Panalgo, and Joseph Menzin will transition to the role of Executive Chairman Oct 17, 2024 · As the leading provider of market access data, analytics and insights, our expert teams of pharmacists, clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. A key use case for our MMIT clients is using lab data for commercial targeting. MMIT Message Monitor captures key payer & IDN decision maker insights around brand and messaging perception. This information is subject to change without notice. MMIT Source gives you complete control of your brand’s promotion strategy including critical market access and restriction comparative data for all brands by therapeutic class. Payers representing 90% of commercial lives indicate that FDA-approved interchangeability is of high or very high importance. And brand managers can use real-world data to deploy field reps more efficiently and create brand strategies tailored to your HCPs’ prescribing behavior. Submission MMIT offers the most robust formulary data set available, spanning all drugs, channels, states, CBSAs and counties, and extending back over a decade. MMIT’s industry-leading platform, Analytics, empowers teams with instant coverage views and access data for various brands and therapeutic areas. From Buy-and-Bill to White Bagging: The Future of Reimbursement Under the Medical Benefit April 20, 2022 Manufacturers and the Mental Health Crisis: How Data and Education Can Improve Patient Access May 26, 2022. Some of the lower-end formularies, which might only have one option in a class, will be forced to include a second option if the drug is selected for negotiation. In her role, she conducts research of drug, indication and policy data and helps MMIT’s clients understand market access from a clinical perspective. “Jan. 5 days ago · Becky Hollenberg, MPH, is a RWD business analyst at MMIT. Optimize formulary standing of your drug. Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. Medicaid may have more covered lives affected by utilization management outliers October 25, 2018 11 For greater insights into payer perspectives, see MMIT’s Biologics & Injectable Index. We are committed to integrity in reporting and bringing transparency to health industry data. 1, 2023 Premium Formulary Exclusions,” Optum Rx. Formulary Management With MMIT’s Application Programming Interface (API) technology, organizations can seamlessly ingest and integrate our industry-leading data into their own data warehouse. MMIT connects comprehensive formulary and policy information to promotional sourcing and tools Lance Wolkenbrod, Sr. Due to the increased focus on being cost-effective, payers are Or is it driven by physicians or payers? In an MMIT analysis of oncology categories, we found that a considerable percentage of therapy changes are influenced by payers. Dinesh Kabaleeswaran. MMIT harnesses the power of real-world data to support end-to-end decision making and increase market access. MMIT, a Norstella company, believes that patients who need lifesaving treatments shouldn’t face delays because of the barriers to accessing therapies. In our first post, Understanding the Basics, we covered the difference between the pharmacy and medical benefit structure, the typical timeline for drug review, and why it’s critical to determine which entity makes formulary and coverage decisions. MMIT Analytics delivers comprehensive formulary, medical policy and restriction information straight to your team with easy-to-use technology. Sep 26, 2019 · Data • July 2017–June 2018 formulary and plan information from Managed Market Insight and Technology (MMIT) – Coverage and formulary placement for 1,958 formularies covering 292 million lives • July 2017–June 2018 utilization and spending information from Symphony Health Integrated Dataverse She is a clinical pharmacist and has been one of MMIT’s clinical subject matter experts for the past 13 years. Research Lab Data: Data from experiments conducted in research laboratories for scientific studies. She earned a master’s degree in public health at Columbia University and a bachelor's from Vanderbilt University. Within MMIT’s solutions, we list the entity that controls the formulary decision as the controller. MMIT offers the most robust formulary data set available, spanning all drugs, channels, states, CBSAs and counties, and extending back over a decade. MMIT’s payer solutions help health plans and PBMs manage medical and pharmacy drug spend with ease. This API highlights MMIT’s Formulary data, and includes all of the supporting resources needed to retrieve Formulary coverage information. MMIT assembles the data into a standardized data set contained as a subset of the MMIT Formulary database, a national database of formularies for over 1100 managed care organizations. Data on file. Types of Lab Data. Jan 18, 2025 · MMIT Network - Offers formulary data & analytics for market research, medication decision & formulary management. This information is used by life science companies to empower the sales reps with knowledge about access to their products and competitor products. MMIT goes beyond market access, charting the path to HCPs and patients. MMIT’s FormTrak Integration in Veeva CRM. With more complete and connected datasets, pharma companies will be able to realize a comprehensive view of each and every patient. By leveraging data-driven insights, embracing innovation, and fostering collaborative partnerships, the industry can navigate the complexities of patient access in 2024 and beyond. You can find her on LinkedIn. Pharma's most trusted formulary data in a free, interactive lookup tool. Real-world data (RWD)—from sources like medical and pharmacy claims, lab tests and results, and EHRs—reveals how patients actually received care. MMIT (Managed Markets Insight & Technology) | 47,815 followers on LinkedIn. Payer or payor is an organization, entity, or person, that sets service rates, collects payments, process claims, and pays provider claims in healthcare. We leverage NorstellaLinQ data to offer you a 360-degree view into the patient journey, revealing the barriers to be overcome. Based on the nation’s largest payer and IDN panel of decision makers who reveal their organization names, Message Monitor provides a “fly-on-the-wall” view of each visit between a pharma company and payer or IDN decision maker, affording actionable insight into competitor Jan 18, 2024 · Leslie Small. About MMIT MMIT (Managed Markets Insight & Technology, LLC) is regarded as a trusted go-to-market partner that helps pharmaceutical manufacturers understand how patients move from diagnosis to treatment while eliminating barriers to care. To understand how PAs function for a particular drug or indication, learn about MMIT’s Patient Access Analytics solution featuring combined coverage, claims, lab and pathways data. In this use case, learn how the company used MMIT’s API to get access to formulary, medical policy, and restriction data, helping the client integrate this information into their existing software About Us. About Us. MMIT’s CoverageFinder can help your team gain more dynamic coverage abilities in a coverage data look-up tool. To promote your therapies to providers before a prescribing decision is made, learn more about MMIT’s Lab Data for Commercial Targeting solution. Prior to MMIT, Carolyn spent numerous years in the payer/PBM space managing formulary teams and technology across both regulated and non-regulated lines of business. FORMULARY NAVIGATOR™ MMIT offers an end-to-end solution that enables payers to manage both pharmacy and medical benefit drugs in one platform. What’s driving this change in coverage? Although payers continue to walk the line between lowering costs and improving outcomes, it’s clear that one of the largest impacts of the new craze for MMIT Analytics delivers comprehensive formulary, medical policy and restriction information straight to your team with easy-to-use technology. It combines data including open and closed claims, lab results About Us. NorstellaLinQ also incorporates proprietary data from About Us. We help you keep source documentation and coverage in sync, manage your fee schedules, and publish formulary data and medical drug lists. Executing a formulary change for a particular health plan requires considerable workload and logistical planning, as touchpoints must be made in such a way as to meet all contractual and legal obligations. ndbmx yagnu tazcxs vxuc bdt hrl vwztwy mgrgeb dzjyz typ